Standout Papers

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-de... 2022 2026 2023 2024142
  1. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 (2022)
    Thierry André, Sara Lonardi et al. Annals of Oncology

Immediate Impact

38 standout
Sub-graph 1 of 16

Citing Papers

Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
2025 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
2 intermediate papers

Works of Arteid Memaj being referenced

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
2022 Standout
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
2021

Author Peers

Author Last Decade Papers Cites
Arteid Memaj 198 56 14 102 69 17 267
Qiaoqi Sui 203 81 6 74 60 20 269
Benjamin Bonhomme 125 42 24 45 78 15 249
Aseem Lal 142 144 12 77 78 17 309
Sang Hoon Ji 196 99 9 63 154 15 308
Estelle Cauchin 126 86 12 85 62 19 225
Konstantinos Papadimitriou 135 71 12 39 59 22 262
Sara Hafezi‐Bakhtiari 131 85 19 88 85 24 258
F. Bacci 101 45 14 103 60 13 242
Yoshifuku Nakayama 111 97 5 84 70 23 289
Christiana Brenin 118 95 6 46 116 15 274

All Works

Loading papers...

Rankless by CCL
2026